Vertex Pharmaceuticals Incorporated vs Workiva Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B), while Workiva Inc trades at $55.02 (market cap $3.21B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 38× Workiva Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| VRTX | WK | |
|---|---|---|
Market Cap | $121.95B | $3.21B |
Sector | Health | Technology |
52-Week High | $529.59 | $93.31 |
52-Week Low | $366.54 | $44.31 |
Enterprise Value | $116.69B | $3.14B |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →